Nahdi Medical (4164) Fundamentals 2026 — P/E 14.7x, Revenue Analysis | SniperIQ
Nahdi Medical (4164) is a SA-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of SAR 11.9B, trading at SAR 91.30 on the SAU. This SniperIQ fundamentals page covers Nahdi Medical's valuation (P/E 14.7x, P/B 4.5x), profitability (net margin 7.8%), revenue (SAR 10.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Nahdi Medical's market cap?
Nahdi Medical (4164) has a market capitalization of approximately SAR 11.9B, trading at SAR 91.30 on the SAU. Market cap moves with the live share price.
What is Nahdi Medical's P/E ratio?
Nahdi Medical's trailing twelve-month P/E ratio is 14.7x, with a price-to-book (P/B) of 4.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Nahdi Medical?
Nahdi Medical runs a net profit margin of 7.8%, a gross margin of 37.0%, and an operating margin of 8.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Nahdi Medical generate?
Nahdi Medical reported revenue of SAR 10.2B for fiscal year 2025, with net income of SAR 831M and earnings per share (EPS) of 6.39. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Nahdi Medical pay a dividend?
Nahdi Medical offers a trailing dividend yield of about 6.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Nahdi Medical financially healthy?
Nahdi Medical carries a debt-to-equity ratio of 0.68x and a current ratio of 1.34x, with a market beta of 0.13. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Nahdi Medical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Nahdi Medical (4164) the key facts are: market cap SAR 11.9B, P/E 14.7x, revenue SAR 10.2B, 52-week range 89.75-132.1. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Nahdi Medical's full fundamentals live
Get Nahdi Medical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.